$0.98
-0.04 (-3.92%)
Open$0.98
Previous Close$1.02
Day High$1.02
Day Low$0.92
52W High$1.79
52W Low$0.20
Volume—
Avg Volume6.23M
Market Cap128.11M
P/E Ratio—
EPS$-0.65
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,965.3% upside
Current
$0.98
$0.98
Target
$20.24
$20.24
$11.64
$20.24 avg
$22.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.82M | 7.64M | 6.13M |
| Net Income | -1,043,017 | -954,590 | -792,337 |
| Profit Margin | -13.3% | -12.5% | -12.9% |
| EBITDA | -1,028,959 | -906,364 | -702,614 |
| Free Cash Flow | -801,636 | -705,541 | -523,657 |
| Rev Growth | -3.5% | +15.6% | +20.8% |
| Debt/Equity | 1.41 | 1.39 | 1.07 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |